dnak

Allergenexperimental

The 70 kilodalton heat shock proteins are a family of conserved ubiquitously expressed heat shock proteins. Proteins with similar structure exist in virtually all living organisms and play crucial roles in the development of cancer, neurodegeneration, apoptosis, regulating sleep, and much more. Intracellularly localized Hsp70s are an important part of the cell's machinery for protein folding, performing chaperoning functions, and helping to protect cells from the adverse effects of physiological stresses. Additionally, membrane-bound Hsp70s have been identified as a potential target for cancer therapies and their extracellularly localized counterparts have been identified as having both membrane-bound and membrane-free structures. There is lot of potential in the Hsp70 protein as a key therapeutic target for developing new drugs for the treatment of sleep disorders, cancer, neurodegeneration, and other related pathological conditions. — Wikipedia

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2010 (NCT01111279)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, desensitized

    Immunity, desensitized

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dnak

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01506375Phase 2Nov 1, 2011ASIT Biotech S.A.
NCT01111279Phase 1Mar 1, 2010ASIT Biotech S.A., Katholieke Universiteit Leuven
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ASIT Biotech S.A.For profit2222010
Katholieke Universiteit LeuvenAcademic/Hospital1012010
2 organizations
Page 1 / 1